Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus
This trial is active, not recruiting.
|Sponsor||National Institute of Allergy and Infectious Diseases (NIAID)|
|Start date||March 2003|
|End date||December 2005|
|Trial size||20 participants|
|Trial identifier||NCT00102934, 5R21-AI055273-02, 5R21AI055273-02, Protocol 834|
Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them. The purpose of this study is to test the effectiveness of a short, intensified course of anti-HIV drugs for controlling HIV infection in adults who have virus resistant to multiple drugs.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Participants will receive enfuvirtide for 6 months
HIV viral load
time frame: Throughout study
Frequency of HIV-specific T cells
time frame: Thoughout study
Male or female participants at least 18 years old.
- HIV viral load of more than 1000 copies/ml
- On stable antiretroviral therapy
- Have multidrug resistance
- Require immunomodulatory drugs
|Official title||Treatment Intensification in HIV-1 Patients With Multi-Drug Resistant Virus|
|Principal investigator||Steven G. Deeks, MD|
|Description||While an HIV infected patient is taking highly active antiretroviral therapy (HAART), drug-resistant HIV may emerge; however, it has been observed that HIV viral loads while on HAART are usually lower than baseline levels. Expansion of the T cell population during early HAART may explain this phenomenon. It is hoped that a short but aggressive HAART regimen to treatment-experienced patients who have drug-resistant virus will produce immune cells that will better control drug-resistant virus. This study will determine if a 6-month HAART regimen intensified by enfuvirtide (T-20) is effective in eliciting a stronger immune response against drug-resistant virus. This study will last 48 weeks. All participants will receive T-20 as part of a HAART intensification regimen; HAART other than T-20 will not be provided by the study. There will be 17 study visits. Prior to beginning treatment intensification, participants will have weekly study visits for three weeks. Once treatment intensification has started, participants will be followed weekly for four weeks, then weekly for four weeks after treatment intensification, then monthly thereafter. Blood collection will occur at each visit.|
Call for more information